Overexpression of BclXL in a human ovarian carcinoma cell line: Paradoxic effects on chemosensitivity in vitro versus in vivo

✍ Scribed by Paul M. Rogers; Philip J. Beale; Mansour Al-Moundhri; Frances Boxall; Lisa Patterson; Melanie Valenti; Florence Raynaud; Steve Hobbs; Stephen Johnston; Lloyd R. Kelland

• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: French
• Weight: 238 KB
• Volume: 97
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.10132

✦ Synopsis

Abstract

The effect of overexpressing the antiapoptotic protein Bcl~XL~ in a human ovarian carcinoma cell line has been investigated in terms of sensitivity to the 2 major drugs used to treat this disease, paclitaxel and cisplatin. Stable transfection of Bcl~XL~ into CH1 cells, which are relatively sensitive to cisplatin, resulted in around 2.7‐fold higher expression in comparison with empty vector controls. However, this level of overexpression did not result in significant resistance in vitro to paclitaxel or cisplatin at the 50% inhibition level, using either short‐term (4‐day) growth inhibition or longer term colony‐forming assays. By contrast, parallel subcutaneous xenograft models of these isogenic ovarian carcinoma cells in vivo, differing only in Bcl~XL~ status, showed that this low‐level Bcl~XL~ overexpression conferred significant resistance to both paclitaxel and cisplatin in comparison with parent, nontransfected tumours. Whereas parent non‐Bcl~XL~ transfected tumours were highly responsive, with the disappearance of tumours for at least 50 days post treatment, tumours overexpressing Bcl~XL~ grew back after 30 and 20 days after treatment with paclitaxel and cisplatin, respectively. These differences in responsiveness to paclitaxel in vivo were not attributable to any significant changes in the delivery of drug to the tumour. These data suggest that the responsiveness of ovarian cancer to paclitaxel and cisplatin in vivo, and therefore perhaps clinically, is influenced by levels of the antiapoptotic protein Bcl~XL~. Such effects may be missed in vitro when using short‐term growth inhibition or clonogenic assays. © 2001 Wiley‐Liss, Inc.